Intravenous silibinin (ivSIL) is a potent antiviral agent against HCV. In vitro silibinin (SIL) inhibits viral replication, possibly by inhibiting HCV RNA polymerase. In this proof-of-concept study, ivSIL was tested in on-treatment non-responders to full-dose of pegylated interferon-α2a/ribavirin (standard of care [SOC]).
Methods
A total of 27 treatment-naive patients with <2 log drop in viral load after 12 weeks or still detectable HCV RNA after 24 weeks of SOC treatment (mean age 54.4 ±6.8 years, male/female 19/8, HCV genotype 1 n=19, 3a n=4 and 4 n=4, liver fibrosis F4 n=14, F3 n=5 and F2 n=3, and interleukin 28B polymorphism C/C n=1, T/C n=22 and T/T n=4) received additionally 20 mg/kg/day SIL (Legalon-SIL®; Rottapharm-Madaus, Monza, Italy) intravenously for 14 or 21 days. Thereafter, pegylated interferon/ribavirin was continued. HCV RNA was quantified by TaqMan® (Roche Diagnostics, Pleasanton, CA, USA).
Results
At the end of ivSIL treatment, 23/27 (85.1%) patients had undetectable HCV RNA. In one of the four remaining patients HCV RNA became undetectable 8 weeks after ivSIL on SOC. Five patients relapsed after ivSIL, three of them responded to repeated administration of ivSIL, but relapsed again. The best predictor of response was a low pre-ivSIL HCV RNA level. A total of 19 patients reached one treatment end point (end of SOC treatment HCV RNA undetectable n=11 and non-response n=8); 8 patients were still on SOC (all HCV-RNA-negative). All 11 patients with end-of-treatment response completed 24 weeks of follow-up; 7 patients remained HCV-RNA-negative and 4 relapsed. Except for a slight increase in bilirubin (mean ±sd 0.98 ±0.35 to 2.12 ±0.99 mg/dl), treatment was well-tolerated.
Conclusions
ivSIL is an effective ‘rescue treatment’ for on-treatment non-responders to full-dose of SOC.
References
1.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
2.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
3.
JensenD.M., MarcellinP., FreilichB.Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med2009; 150: 528–540.
4.
PoynardT., ColomboM., BruixJ.Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology2009; 136: 1618–1628.e2.
5.
Di BisceglieA.M., ShiffmanM.L., EversonG.T.Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med2008; 359: 2429–2441.
6.
HoofnagleJ.H.Course and outcome of hepatitis C. Hepatology2002; 36Suppl 1: S21–S29.
7.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med2009; 360: 1839–1850.
8.
McHutchisonJ.G., EversonG.T., GordonS.C.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med2009; 360: 1827–1838.
9.
McHutchisonJ.G., MannsM.P., MuirA.J.Telaprevir for previously treated chronic HCV Infection. N Engl J Med2010; 362: 1292–1303.
10.
FerenciP., ScherzerT.M., KerschnerH.Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology2008; 135: 1561–1567.
11.
BiermerM., BergT.Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin. Gastroenterology2009; 137: 390–391.
12.
GazákR., WalterovaD., KrenV.Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem2007; 14: 315–338.
13.
PolyakS.J., MorishimaC., ShuhartM.C.Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology2007; 132: 1925–1936.
14.
Mehrab-MohseniM., SteuerwaldN., SendiH.Legalon-Sil down-regulates HCV core and NS5A expression in human hepatoma lines expressing full-length HCV. Hepatology2009; 50 Suppl: 685A.
15.
Ahmed-BelkacemA., AhnouN., BarbotteL.Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology2010; 138: 1112–1122.
WagonerJ., NegashA., KaneO.J.Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology2010; 51: 1912–1921.
18.
PietrangeloA., BorellaF., CasalgrandiG.Antioxidant activity of silybin in vivo long-term iron overload in rats. Gastroenterology1995; 109: 1941–1949.
19.
DehmlowC., ErhardJ., de GrootH.Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology1996; 23: 749–754.
20.
BoigkG., StroedterL., HerbstH.Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology1997; 26: 643–649.
21.
PolyakS.J., MorishimaC., LohmannV.Identification of hepatoprotective favonolignans from silymarin. Proc Natl Acad Sci U S A2010; 107: 5995–5999.
22.
FerenciP., DragosicsB., DittrichH.Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol1989; 9: 105–113.
23.
HawkeR.L., SchrieberS.J., SouleT.A.Silymarin ascending multiple oral dosing Phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol2010; 50: 434–449.
24.
LeeS.S., FerenciP.Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther2008; 13Suppl 1: 9–16.
25.
StättermayerA.F., StauberR., HoferH.Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol2011; 9: 344–350.e2.
26.
CastéraL., VergniolJ., FoucherJ.Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology2005; 128: 343–350.
27.
ChevalierS., Ahmed-BelkacemA., SoulierA.In vivo and in vitro resistance to silibinin, a component of silymarin and potent inhibitor of HCV replication. J Hepatol2010; 52 Suppl. 1: S298.
28.
DieterichD.T., RizzettoM., MannsM.P.Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin. J Viral Hepat2009; 16: 833–843.
29.
RyderS.D., IrvingW.L., JonesD.A.Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut2004; 53: 451–455.
30.
SarrazinC., RouzierR., WagnerF.SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology2007; 132: 1270–1278.
31.
BaconB.R., GordonS.C., LawitzE.Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1207–1217.
32.
BiermerM., StoehrL., SchlosserB.Silibinin as a rescue treatment for HCV- infected patients showing suboptimal virologic response to standard combination therapy. J Hepatol2010; 52Suppl 1: S16.
33.
ScherzerT.M., StauberR., MaieronA.Undetectable HCV RNA after silibinin iv treatment is associated with high on treatment response rates in HCV null responders. Hepatology2010; 52 Suppl: 723A.
34.
FerenciP., LaferlH., ScherzerT.M.Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology2010; 138: 503–512.e1.
